Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
76.90
-0.14 (-0.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astrazeneca Plc ADR
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
July 27, 2023
From
AstraZeneca
Via
Business Wire
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
July 03, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated sustained overall survival benefit in advanced liver cancer with an unprecedented one in four patients alive at four years in HIMALAYA Phase III trial
June 29, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Friday Morning
April 21, 2023
Via
Investor Brand Network
AstraZeneca PLC (NASDAQ: AZN) Records 52-Week High Tuesday Morning
April 18, 2023
Via
Investor Brand Network
AstraZeneca PLC (NASDAQ: AZN) Sets New 52-Week High in Wednesday Session
April 12, 2023
Via
Investor Brand Network
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
June 28, 2023
From
AstraZeneca
Via
Business Wire
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
June 26, 2023
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t
Via
MarketBeat
AstraZeneca announces innovative partnership with Vanguard Renewables to decarbonize its United States sites
June 13, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca PLC (NASDAQ: AZN) Climbs to New 52-Week High
April 06, 2023
Via
Investor Brand Network
Astrazeneca Plc (NASDAQ: AZN) Highlighted for Surprising Price Action
April 05, 2023
Via
Investor Brand Network
Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
June 12, 2023
From
AstraZeneca
Via
Business Wire
Datopotamab deruxtecan combinations showed encouraging tumor responses in patients with advanced non-small cell lung cancer in TROPION-Lung02 Phase Ib trial
June 05, 2023
From
AstraZeneca
Via
Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
June 05, 2023
From
AstraZeneca
Via
Business Wire
ANDEXXA Phase IV Trial Stopped Early After Achieving Pre-specified Criteria on Hemostatic Efficacy Versus Usual Care
June 05, 2023
From
AstraZeneca
Via
Business Wire
TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years in ADAURA Phase III trial
June 04, 2023
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian cancer without tumor BRCA mutations in the DUO-O Phase III trial
June 03, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial
June 02, 2023
From
AstraZeneca
Via
Business Wire
LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
June 01, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
May 26, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
May 25, 2023
From
AstraZeneca
Via
Business Wire
New AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
May 23, 2023
From
AstraZeneca
Via
Business Wire
TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
May 17, 2023
From
AstraZeneca
Via
Business Wire
FARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
May 09, 2023
From
AstraZeneca
Via
Business Wire
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
May 02, 2023
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks
April 24, 2023
From
AstraZeneca
Via
Business Wire
IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial
April 16, 2023
From
AstraZeneca
Via
Business Wire
3 Healthcare Dividend Payers With Big Price Growth
April 14, 2023
Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers.
Via
MarketBeat
AstraZeneca reinforces commitment to advancing science for patients with chronic kidney disease and hyperkalemia at NKF Spring Clinical Meeting 2023
April 11, 2023
From
AstraZeneca
Via
Business Wire
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
March 27, 2023
Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.